Search research articles
Contact Us
Filters
Showing results (1-10 of 21) with videos related to
Page
of 3
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 5, 2014
Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infection in the AVIATOR study
Fred Poordad, Kosh Agarwal, Ziad Younes, et al.
Systematic Biology
|
December 29, 2010
Improving marginal likelihood estimation for Bayesian phylogenetic model selection
Wangang Xie, Paul O Lewis, Yu Fan, et al.
Systematic Biology
|
November 7, 2013
Posterior predictive Bayesian phylogenetic model selection
Paul O Lewis, Wangang Xie, Ming-Hui Chen, et al.
Journal of Pediatric Gastroenterology and Nutrition
|
July 4, 2024
Safety and efficacy of linaclotide in children aged 2-5 years with functional constipation: Phase 2, randomized study
Carlo Di Lorenzo, Jon Robert, Gerardo Rodriguez-Araujo, et al.
Statistics in Biosciences
|
March 14, 2013
A Bayesian Approach to Pathway Analysis by Integrating Gene-Gene Functional Directions and Microarray Data
Yifang Zhao, Ming-Hui Chen, Baikang Pei, et al.
Journal of Crohn'S & Colitis
|
June 9, 2021
Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis
Subrata Ghosh, Yuri Sanchez Gonzalez, Wen Zhou, et al.
Contemporary Clinical Trials
|
August 19, 2017
Dose-ranging design and analysis methods to identify the minimum effective dose (MED)
Yijie Zhou, Su Chen, Danielle Sullivan, et al.
Antimicrobial Agents and Chemotherapy
|
June 24, 2015
Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir
Preethi Krishnan, Rakesh Tripathi, Gretja Schnell, et al.
Plos One
|
October 5, 2018
Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir
Gretja Schnell, Preethi Krishnan, Rakesh Tripathi, et al.
Antimicrobial Agents and Chemotherapy
|
August 1, 2018
Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials
Preethi Krishnan, Tami Pilot-Matias, Gretja Schnell, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 21) with videos related to
Sort By:
Page
of 3
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 5, 2014
Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infection in the AVIATOR study
Fred Poordad, Kosh Agarwal, Ziad Younes, et al.
Systematic Biology
|
December 29, 2010
Improving marginal likelihood estimation for Bayesian phylogenetic model selection
Wangang Xie, Paul O Lewis, Yu Fan, et al.
Systematic Biology
|
November 7, 2013
Posterior predictive Bayesian phylogenetic model selection
Paul O Lewis, Wangang Xie, Ming-Hui Chen, et al.
Journal of Pediatric Gastroenterology and Nutrition
|
July 4, 2024
Safety and efficacy of linaclotide in children aged 2-5 years with functional constipation: Phase 2, randomized study
Carlo Di Lorenzo, Jon Robert, Gerardo Rodriguez-Araujo, et al.
Statistics in Biosciences
|
March 14, 2013
A Bayesian Approach to Pathway Analysis by Integrating Gene-Gene Functional Directions and Microarray Data
Yifang Zhao, Ming-Hui Chen, Baikang Pei, et al.
Journal of Crohn'S & Colitis
|
June 9, 2021
Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis
Subrata Ghosh, Yuri Sanchez Gonzalez, Wen Zhou, et al.
Contemporary Clinical Trials
|
August 19, 2017
Dose-ranging design and analysis methods to identify the minimum effective dose (MED)
Yijie Zhou, Su Chen, Danielle Sullivan, et al.
Antimicrobial Agents and Chemotherapy
|
June 24, 2015
Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir
Preethi Krishnan, Rakesh Tripathi, Gretja Schnell, et al.
Plos One
|
October 5, 2018
Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir
Gretja Schnell, Preethi Krishnan, Rakesh Tripathi, et al.
Antimicrobial Agents and Chemotherapy
|
August 1, 2018
Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials
Preethi Krishnan, Tami Pilot-Matias, Gretja Schnell, et al.
Page
of 3